The phrase ‘build it and they will come’ dates all the way back to the Old Testament, and in more...
Read more
HotSpot Therapeutics recently announced FDA clearance of our Investigational New Drug (IND) application for HST-1011, our small molecule allosteric inhibitor...
Read more
Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4) in 2011…
Read more